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ABSTRACT 
Epigenetics play a role not just in the normal functioning of the cell and its 
development, but also in diseases like neurological diseases and cancer. 
Epigenetic therapies can help to resolve non-identical problems of these 
pathophysiological conditions. Cancer is a complex disease with both 
genetic and epigenetic origins. The importance of epigenetics in cancer 
has been identified, and the field has emerged rapidly in recent years. 
Epigenetic and genetic alterations contribute to the initiation and 
progression of cancer. Epigenetic modifications introduced genetic 
changes, and usually occur at an early stage in development of a 
neoplasm, but may also be involved in its invasion and spread. Recent 
technological advances in genetics and epigenetics offer a better 
understanding of the underlying epigenetic alterations during initiation 
and in the progression process of the human tumors. 
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Introduction 
The term epigenetics currently refers to the 
mechanisms of temporal and spatial control of 
gene activity that do not depend on the DNA 
sequence, influencing the physiological and 
pathological development of an organism. The 
molecular mechanisms by which epigenetic 
changes occur are complex and cover a wide 
range of processes including paramutation, 
bookmarking, imprinting, gene silencing, 
carcinogenesis progression, and most 
importantly regulation of heterochromatin and 
histone modifications. The term ‘epigenetic’ was 
coined by the developmental biologist, Conrad 
Hal Waddington, in 1942.1 Robin Holliday 
defined epigenetics as the study of the 
mechanisms of temporal and spatial control of 
gene activity during the development of 
complex organisms. One of the best examples of 
epigenetic changes in eukaryotic biology is the 
different developmental stages from the single 
fertilized egg, the zygote, to a fully grown 
organism. Modern biology uses epigenetic 
changes as molecular tools for finding and 
treating various diseases including cancer.2  
Cancer is a multi-step process derived from 
combinational crosstalk between genetic 
alterations and epigenetic influences through 
various environmental exposures. Moreover, it 
has been well documented that environmental 
exposure to nutritional, dietary, physical, and 
chemical factors could alter gene expression and 
modify individual genetic susceptibility through 
changes in the epigenome (Figure 1).3 Several 
distinct but intertwined mechanisms are known 
to be part of the epigenome which includes 
DNA methylation, histone acetylation, poly-
ADP ribosylation and ATP-dependent chromatin 
remodeling.3,4-7  
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Figure 1: Factors contributing to 
carcinogenesis.3 
Epigenetic mechanisms controlling gene 
transcription are frequently involved in cell 
proliferation, differentiation, and survival and 
are casually linked with malignant development. 
Alterations in epigenetic processes including 
chromatin modifications such as DNA 
methylation and histone acetylation are common 
targets studied in cancer epigenomics. It has 
been shown that half of all tumor suppressor 
genes are inactivated in cancers more often by 
epigenetic, than by genetic, mechanisms. 
Growing evidence suggests that bioactive 
dietary components impact epigenetic processes 
often involved with reactivation of tumor 
suppressor genes, activation of cell survival 
proteins, and induction of cellular apoptosis in 
many types of cancer. In addition to 
transcriptional silencing of tumor suppressor 
genes and protein expression, noncoding 
microRNAs can regulate expression of a myriad 
of cellular proteins by affecting mRNA stability 
and translation by epigenetic processes in cancer 
progression. Interestingly, these miRNAs can 
control the expression of various epigenetic 
modifying enzymes such as DNA 
methyltransferases (DNMTs), histone 
methyltransferases (HMTs), and histone 
deacetylases (HDACs) involved in 
carcinogenesis processes. Recent evidence 
suggests that bioactive dietary components can 
also target various oncogenic or tumor 
suppressive miRNAs to alter the gene 
expression profile in cancer prevention. In fact, 
miRNA profiles are now being used to classify 
human cancers. Further, miRNAs can directly or 
indirectly regulate cancer progression either by 
acting as cancer suppressors or by altering 
epigenetic modifying enzymes, respectively. In 
particular, miRNA-221 and miRNA-222 target, 
an oncogene, and therefore function as tumor 
suppressors in erythroblastic cells and other 
human solid tumors. Furthermore, the miRNA-
29 family can directly regulate the expression of 
DNMTs and increase expression of DNMT 
thereby causing a global genomic hyper 
methylation and silencing of methylation 
sensitive tumor suppressor genes such as FHIT 
and WWOX.1,5,8-11 
Epigenetic mechanisms related to 
cancer  
DNA methylation 
DNA methylation plays a well-defined role in 
both development and disease, including 
cancer.4 First identified in 1975, CpG island 
(CGI) methylation was shown to function as a 
relatively stable alteration on DNA that can 
serve to silence gene transcription. We now 
understand that DNA methylation is much more 
dynamic and complex, with diverse epigenetic 
consequences linked to varied genomic locations 
of where this mark occurs. For example, DNA 
methylation at gene promoter CGIs potently 
blocks the initiation of transcription, whereas 
methylation within CpG-poor gene bodies may 
actually facilitate elongation and influence 
patterns of alternate splicing. In addition, DNA 
methylation is frequently found in repeat-rich 
areas of the genome and is vital for both 
chromosomal and genomic stability, possibly 
through the repression of retroviral transposons. 
Still, the role for this epigenetic mark at other 
regulatory regions, such as enhancers and 
insulators, has yet to be determined. Regardless, 
aberrant methylation in human cancer is a 
defining feature, with global promoter CGI 
hypermethylation and non-CGI hypomethylation 
widely reported. Furthermore, local variations in 
methylation at only several key loci have been 
shown to be sufficient for carcinogenesis. 
Importantly, these altered patterns of DNA 
epigenetic marks are frequently accompanied by 
a critical imbalance in transcriptional programs 
involving differentiation and stem cell 
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maintenance, thereby initiating carcinogenesis 
and sustaining growth. DNA methylation can 
function to silence tumor suppressor genes along 
with genetic mutations. For example, in the case 
of hereditary gastric cancer, methylation of 
CDH1 (which encodes the E-cadherin tumor 
suppressor) can function as a “second hit” and 
cause gastric cancer when the first allele is 
mutated. In sporadic cancers, tumor suppressor 
genes that are mutated in hereditary versions of 
the disease are frequently silenced by DNA 
methylation instead. For example, in hereditary 
nonpolyposis colon cancer (HNPCC), MLH1 
inactivation via mutation can lead to 
microsatellite instability (MSI) and 
tumorigenesis, whereas in sporadic colon 
cancers, MLH1 is frequently silenced by 
methylation. These data and others indicate that 
aberrant DNA methylation can work along with 
genetic alterations to promote tumorigenesis 
(Figure 2).12,13 
 
Figure 2: DNA methylation-mediated 
aberrant gene silencing in cancer involves 
transcriptional repressive complexes in the 
gene promoter region and interactions 
between DNA methylation machinery, 
chromatin modifiers (such as histone 
deacetylase, HDAC) and polycomb (PcG) 
proteins. HAT: histone acetylase. Pol II: RNA 
polymerase II.12,13 
Pharmacological inhibition of individual 
components in the repressive complex with 
DNMT inhibitors and HDAC inhibitors, either 
alone or in combination, may result in DNA 
demethylation and complex disintegration 
leading to reactivation of critical genes and 
reversal of genome-wide epigenetic alterations 
in cancer through resetting multiple cellular 
processes, including lineage commitment, 
immunomodulation, major cell signaling 
pathways, programmed cell death, and others.  
Histone acetylation and methylation 
In 1964, Vincent Allfrey prophetically surmised 
that histone modifications might have a 
functional influence on the regulation of 
transcription. Many histone modifications play 
important roles in epigenetic alterations, and 
acetylation and methylation are the two main 
histone modifications that have been clinically 
linked as predictors for cancer progression.14 
These histone modifications induce chromatin 
alterations that allow access to the various 
transcriptional activators and/or repressors at 
gene promoters, and they therefore play an 
important role in gene regulation and 
carcinogenesis. Histones are subject to different 
types of reversible covalent posttranslational 
modifications including, but not limited to, 
lysine acetylation, lysine and arginine 
methylation, serine and threonine 
phosphorylation, and lysine ubiquitination and 
sumoylation. These modifications occur 
primarily within the histone amino-terminal tails 
protruding from the surface of the nucleosome 
as well as on the globular core region and 
regulate key cellular processes such as 
transcription, replication, and repair. Specific 
histone modifications appear to act as 
programmed “codes” which can be identified by 
specific proteins to bring about distinct 
downstream events such as transcriptional 
activation or repression. The mechanism of 
inheritance of this histone code, however, is still 
not fully understood (Figure 3).15,16 
Chromatin remodeling 
In addition to gene regulation via covalent 
histone tail modifications, the ATP-dependent 
chromatin remodelers also shape chromatin 
structure and thereby affect gene expression 
patterns. In the past several years, protein 
components of the SWI/SNF complex have been 
found to be frequently inactivated in cancer, and 
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subsequent work has solidified their status as 
bona fide epigenetic tumor suppressors.17,18 
 
Figure 3: Epigenetic enzymes and their 
inhibitors. The figure shows the interactions 
between epigenetic enzymes (writers, erasers, 
readers) and nucleosomes. The nucleosome core 
consists of a histone octamer (mainly two copies 
each of H2A, H2B, H3 and H4) that is wrapped 
by a nuclear DNA strand of 147 bp. DNA 
methylation and hydroxymethylation are 
depicted as black and grey circles, respectively. 
DNA methylation is induced by DNA 
methyltransferases (DNMTs). To inhibit DNA 
methylation, DNMT inhibitors (DNMTis) are 
used to target and suppress DNMTs. Histone 
tales can be post-transcriptionally modified 
using enzymes such as histone acetyltransferases 
(HATs). Histone acetylation can be inhibited by 
histone deacetylases (HDACs), and HDAC 
inhibitors (HDACis) can be used as HDAC 
suppressors.15 
Epigenetic in cancer diseases 
Although in the last decade several cancer 
pathologies have been associated to specific 
epigenetic changes, the way in which epigenetic 
modifications are regulated is still largely 
unknown. In this section we describe the current 
knowledge linking various cancer types with 
epigenetic targets, considering that demonstrated 
cause-consequence might not necessarily 
indicate that these targets are validated for 
anticancer drug design purposes. In this review 
we summarized the connections between the 
most important cancer diseases and the various 
classes of epigenetic targets, associating them to 
relevant drug discovery information.19-21 
Breast cancer 
Epigenetic alterations such as DNA methylation 
and chromatin remodeling play a significant role 
in breast cancer development and, although 
extensive research has been done, the causes, 
mechanisms and therapies of breast cancer are 
still to be fully elucidated.[22-24] Epigenetic 
changes in different classes of this type of 
cancer have been studied, including: estrogen 
receptor positive (ER+), that are estrogen-level 
dependent; estrogen receptor negative (ER-), 
whose tumor cells are not responsive to estrogen 
thus resistant to antiestrogenic drugs such as 
tamoxifen and aromatase inhibitors; 
progesterone receptor (PR); and human 
epidermal growth factor 2 (HER2) related 
cancers. A number of genes have been identified 
to be aberrantly methylated in breast cancer and 
their number is rapidly growing. 25-29 
Lung cancer 
Epigenetic changes in lung cancers contribute to 
cell transformation by modulating chromatin 
structure and specific expression of genes, these 
include DNA methylation patterns, covalent 
modifications of histone and chromatin by 
epigenetic enzymes, and micro- RNA. All these 
changes are involved in the silencing of tumor 
suppressor genes and enhance the expression of 
oncogenes. Genome-wide technologies and 
bioinformatics studies demonstrated that global 
alterations of histone patterns are linked to DNA 
methylation and are causal in lung cancer. These 
techniques were also used for the prediction of 
specific miRNAs targeting the epidermal growth 
factor receptor (EGFR) in lung cancer. Many 
genes were found to be silenced by methylation 
promoters in lung cancers in response to 
radiation stimuli. DNA methylation patterns 
may also predict early recurrence of stage I non-
small-cell lung carcinoma (NSCLC).23,30-32 
Pancreatic cancer  
Pancreatic cancer (PC) is by far an incurable 
disease with an estimated 168,800 annual 
fatalities worldwide translating to approximately 
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20 deaths every hour. PC is often called ‘the 
silent killer’ because early stages of the disease 
often does not cause any symptoms so this leads 
to PC being diagnosed at a very late stage when 
it is not amenable to surgery or standard 
chemotherapy Emerging research in this area 
has led to the identification and characterization 
of deregulated miRNAs, which have generated a 
renewed interest and hope in that novel targeting 
of miRNAs may lead to a better clinical 
outcome for patients diagnosed with PC. 
However, recent evidence suggests that miRNAs 
are also under a highly coordinated system of 
epigenetic regulation emphasizing the fact that 
the design of miRNAs as targeted therapy may 
not be as simple as originally anticipated. For a 
successful miRNA-based therapeutic regimen, a 
holistic integrated approach may be required to 
take into account because of these emerging 
epigenetic regulatory mechanisms.33,34 
Kidney cancer 
Kidney cancer accounts for 2% of all adult 
cancer malignancies and the majority of them 
(80-85%) are renal cell carcinomas (RCCs) 
originated from the renal parenchyma. While the 
direct causes of this type of cancer are still 
vaguely defined, smoking and chemical 
carcinogens (e.g. asbestos and organic solvents) 
have been related to renal carcinogenesis. 
Furthermore pathologies like obesity, 
hypertension and the use of antihypertensive 
medications, have been reported as risk-factors 
for RCCs. Stepwise accumulation of DNA 
methylation has been observed by comparing 
normal renal tissues, renal tumor tissues and 
non-tumor renal tissues of patients with renal 
tumors.35 These results highlighted that regional 
CpG patterns may participate in the early and 
precancerous stage of renal carcinogenesis. On 
the contrary, DNA hypomethylation does not 
seem to be a major event during renal 
carcinogenesis. DNA methylation alterations at 
a precancerous stage may further predispose 
renal tissue to epigenetic and genetic alterations, 
generating more malignant cancers and even 
determining the patient outcome. At present 
there are few clinical trials of Phase I/II for 
testing inhibitors of HDACs in advanced 
RCC.23,36 
Gastric cancer 
Gastrointestinal (GI) carcinogenesis causes 
some of the most common types of tumors 
worldwide, including esophagus, stomach, 
bowel, and anus. Even thought it has been 
recognized that the major reason for GI 
carcinogenesis resides in at least one genetic 
mutation that either activates an oncogene or 
inhibits the function of a tumor suppressor gene, 
recent data indicate that epigenetic abnormalities 
are critical in regulating benign carcinogenesis 
and eventual malignant transformation in 
gastorointestinal (GI) carcinogenesis. In 
particular aberrant histone acetylation regulated 
by HATs and HDACs have been linked to 
gastric cancer. Epigenetic alterations have also 
been identified in presence of Epstein-Barr 
virus, while Helicobacter pylori, which 
constitutes a main cause of gastric cancer, was 
shown to reduce HDACs activity. These data 
suggest that pharmacological actions of HDACi 
in GI might be detrimental or beneficial 
depending on the clinicopathological context. 
Despite the fact that various links between GI 
cancer and HATs and HDACs have been 
identified, comparing to other cancers, fewer 
progresses have been reported to treat GI 
carcinogenesis with epidrugs. A Phase I study 
has combined Vorinostat with radiotherapy in 
GI carcinoma. This, as well as other studies, 
created foundations for additional initiatives to 
improve the therapeutic potential of HDACi and 
other epigenetic enzymes for GI tumors.23,37,38 
Hepatocellular carcinoma (liver cancer) 
Hepatocellular carcinoma (HCC) originates 
from hepatocytes and is the most common liver 
cancer. Cancer rates and etiology of HCC vary 
considerably by age, gender, ethnic origin, 
lifestyle (in particular alcohol abuse and 
environmental pollution. Other factors include 
the infection by hepatitis B and C virus (HBV 
and HCV), exposure to aflatoxins, hypertension 
and diabetes. Both geetic and epigenetic factors 
form the molecular basis of HCC. Epigenetic 
alterations may predispose to genetic changes 
and, vice versa, genetic changes may also 
initiate aberrant epigenetic modifications. DNA 
methylation and various histone modifications, 
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as well as RNA interference, have been reported 
as epigenetic events contributing to HCC 
development. It should be remarked that the use 
of epigenetic biomarkers for detecting 
hepatocellular carcinoma has expanded the 
potential for non-invasive screening of high-risk 
populations. However, the road to develop 
small-molecule compounds targeting epigenetic 
enzymes for HCC cancer treatment is at its 
beginning. Presently only HDAC is have been 
studied for the treatment of HCC.23,39 
Gynecologic cancer 
Gynecologic cancer includes any cancer that 
occurs in the female reproductive organs. There 
are five frequently occurring gyne-cologic 
cancers: ovarian, cervical, endometrial (uterine), 
vaginal, and vulvar. Gynecologic cancers 
usually have high mortality rates, because it is 
difficult to detect the cancer in early stage. 
Ovarian cancer is the most lethal gynecologic 
cancer. In advanced ovarian and endometrial 
carcinomas, current therapies that are initially 
responsive evolve to a fully drug-resistant 
phenotype. Among the factors that contribute 
negatively to the progression and therapeutic 
resistance against ovarian and endometrial 
cancer, there are several genetic mutations and 
epigenetic anomalies which are frequent in both 
malignancies.40,41  
Conclusions 
In this review, we described the epigenetic 
mechanism that contributes to assets 
maintenance of self-renewal feature for cancer 
cell, which include change in DNA and histone- 
methylation, chromatin remodeling in many 
different condition. The development of small 
molecule inhibitors for specific methyl-
transferases and methyl-readers has provided 
novel strategies to target the epigenetic 
processes that are disrupted in malignant cells. 
Sequence-specific, engineered proteins attached 
to chromatin remodeling enzymes have the 
pivotal advantage to target specific locus 
associated with malignant progression. 
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